García AP, Horak GC

Language: Spanish
References: 19
Page: 153-157
PDF size: 96.45 Kb.

ABSTRACT

Introduction: Overweight and obesity are problems that affect about 70% of the population, aged 30 to 60 years. This increasing incidence requires new strategies that could facilitate weight reduction. The proposed strategy in this study was the fixed combination of sibutramine 15 mg/carnitine 600 mg, plus diet and exercise. Objective: To evaluate the effectiveness and security of carnitine/sibutramine in combination for weight reduction in overweight and obese subjects. Methods: Sixty overweigth and obese subjects were included. A nutritional program including a 1,500 kcal diet was established and was accompanied by an exercise program during the 12 weeks of the study. Results: The obtained results showed an unexpected weight reduction of 7-10%, in contrast to the 5% reported with sibutramine alone in the literature. Adverse events occurred in 7 cases were mild and consisted of constipation and insomnia. Conclusions: Patients treated with sibutramine/carnitine had a significant weight loss, with a good safety profile.

REFERENCES

1. Mokdad et al. Prevalence of obesity, diabetes and obesity related health risk factors 2001. JAMA 2003; 289: 76-79.

2. Mokdad AH, Marks JS, Stroup Gerberding JL. Actual causes of death in United States. JAMA 2004; 291.

3. Gundlah C, Martin KF, Heal DJ, Schjott, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmac Exp Ther 1997; 283: 581-591.

4. Walsh KM, Leen E, Lean MEJ. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999; 23: 1009-1015.

5. Morales VEC y cols. Obesidad. Un problema de peso. Rev Mex Cardiol 2007; 18(4): 163-172.

6. Mak-Soon Lee. L-Carnitine stimulates lipolysis via induction of the lipolytic gene expression and suppression of the adipogenic gene expression in 3T3-L1 adipocytes. J Med Food 2006; 9(4): 468-473.

7. Lee MS. L-carnitine stimulates lipolysis via induction of the lipolytic gene expression and suppression of the adipogenic gene expression in 3T3-L1 adipocytes. J Med Food 2006; 9(4): 468-73.

8. Rubio MA. Consenso SEEDO 2007 para la evaluación de sobrepeso y la obesidad y establecimiento de intervención terapéutica.

9. García Ponte L. Rev Esp Econ Salud 2003; 2(6): 342-349.

10. Tein I, Bukovac SW, Xie-ZW. Characterization of the human plasmalemmal carnitine transporter in cultured skin fibroblasts. Arch Biochem Biophys 1996; 329: 145-155.

11. Youn-Soo Cha. Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. Asia Pac J Clin Nutr 2008; 17(S1): 306-308.

12. Maebashi M, Sato M, Kawamura N, Imamura A, Yoshinaga K. Lipid lowering effect of carnitine in patients with IV hyperlipoproteinemia. Lancet 1978; 14: 805-807.

13. Kuhajda FP. Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity. Current Opinion in Investigational Drugs 1472 2007.

14. Rebouche ChJ. Metabolismo de la carnitina y función en humanos. Ann Rev Nutr 1986; 6: 41-66.

15. Jones SP et al. Long term weight loss with sibutramine. Int J Obes Relat Metab Disord 1995; 19: 41.

16. Apferlbaum M et al. Long term maintenance of weight loss after a very low calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-184.

17. James WP, Astrup A. For de STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356: 2119-2125.

18. Clouet P, Sempore G, Tsoko, Gresti J, Demarquoy J, Niot I, Bezard J, Martin-Privat P. Effect of short- and long-term treatments by a low level of dietary L-carnitine on parameters related to fatty acid oxidation in Wistar rat. Biochim Biophys Acta 1996; 1299: 191-197.

19. Encuesta Nacional de Salud y Nutrición ENSANUT 2006.